[
  {
    "ts": null,
    "headline": "Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort",
    "summary": "WILMINGTON, Mass., December 11, 2025--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as well as a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to expedite the developme",
    "url": "https://finnhub.io/api/news?id=b0068ad170a44b8c0e29dd711887647af613dc4ee16b4663bc471ca3dfdf9394",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765458000,
      "headline": "Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort",
      "id": 137758247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "WILMINGTON, Mass., December 11, 2025--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as well as a comprehensive ecosystem of discovery, development, and manufacturing capabilities, to expedite the developme",
      "url": "https://finnhub.io/api/news?id=b0068ad170a44b8c0e29dd711887647af613dc4ee16b4663bc471ca3dfdf9394"
    }
  }
]